Facility readiness resources
These resources are available to help your facility operationalize RRMM bispecifics from J&J,
TECVAYLI® and TALVEY®.
TECVAYLI® and TALVEY® are available only through a restricted program under Risk Evaluation and Mitigation Strategy (REMS) because of the risks of Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). The program is called TECVAYLI® and TALVEY® REMS.
Further information about the TECVAYLI® and TALVEY® REMS program is available at www.TEC-TALREMS.com or by telephone at 1-855-810-8064.
Your Pharmacy/Healthcare Settings can enroll in the TECVAYLI® and TALVEY® REMS program by following these four steps:
Your Pharmacy/Healthcare Settings can enroll in the TECVAYLI® and TALVEY® REMS program by following these four steps:
- Designate an Authorized Representative for the Pharmacy and Healthcare Setting
- Have the Authorized Representative review the Pharmacy and Healthcare Setting Training Program
- Have the Authorized Representative complete the Pharmacy and Healthcare Setting Enrollment Form and submit it to the REMS
- Train all relevant staff involved in dispensing TECVAYLI® and/or TALVEY® on the REMS requirements using the Pharmacy and Healthcare Setting Training Program
As part of the TECVAYLI® and TALVEY® Risk Evaluation and Mitigation Strategy (REMS) requirement, J&J is required to conduct audits of certified Pharmacies and Healthcare Settings (HCS) within 180 calendar days after receiving their first shipment of TECVAYLI® or TALVEY®, and annually thereafter. This is to ensure that all REMS processes and procedures are in place, functioning, and support the REMS Program requirements. This guide will help you be audit-ready.
These resources are available to help your facility access TECVAYLI® and TALVEY® for RRMM.
Click the links below to download the TECVAYLI® and TALVEY® resources you may need.
TECVAYLI®
These health systems instructions are for updating relapsed or refractory multiple myeloma order sets with bispecifics from J&J within the approved indication and consistent with the Prescribing Information.
Click the links below to download the TECVAYLI® and TALVEY® clinical resources you may need.
Providers & care team readiness resources
These resources are designed to ensure your team is prepared to treat with TECVAYLI® or TALVEY® for RRMM.
This all-in-one site provides TECVAYLI® and TALVEY® REMS information, including prescriber enrollment, prescriber training, AR management, and additional resources for providers.
All healthcare providers involved in the prescribing of TECVAYLI® or TALVEY® are trained on the TECVAYLI® and TALVEY® REMS requirements and must successfully complete the Knowledge Assessment.
Prescribers can become certified in the TECVAYLI® and TALVEY® REMS in four steps:
Prescribers can become certified in the TECVAYLI® and TALVEY® REMS in four steps:
- Review the Prescriber Training Program & AR Management Guide
- Complete the Knowledge Assessment and submit it to the REMS program
- Complete the Prescriber Enrollment Form and submit it to the REMS program
- Before treatment initiation (first dose), counsel patients and/or their caregivers using the Patient Wallet Card. Complete and provide patients or their caregivers with the Patient Wallet Card. Counsel patients that they should be hospitalized and monitored for signs and symptoms of Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), for 48 hours after administration of all doses within the step-up dosing schedule.
These resources provide education and additional support for providers and care teams treating patients with TECVAYLI® or TALVEY® for RRMM.
Click the links below to download the TECVAYLI® and TALVEY® resources you may need.
TECVAYLI®
TALVEY® Hands-on Conversation Series
TALVEY® Hands-on Conversation Series
Effectively managing RRMM treatment greatly benefits from hands-on knowledge. In this podcast made for healthcare professionals, you’ll hear guidance and personal experiences from experts caring for patients living with RRMM. Learn by example from patient case studies and conversations designed to educate about TALVEY® eligibility, AR management, dosing, and transition of care.
These resources help healthcare providers and teams deliver continuous care to patients, whether at a single site or across multiple locations, throughout both their initial and ongoing treatment with TECVAYLI® or TALVEY® for RRMM.
Click the links below to download the TECVAYLI® and TALVEY® resources you may need.
Treatment Locator
The Certified Physicians listed in the Treatment Locator link below have opted in to be included on this website. Therefore, others could be certified and not listed here.
Once the clinical decision has been made to prescribe a J&J medicine, Johnson & Johnson has resources to help you support your patients.
J&J withMe is your single source for access, affordability, and treatment support programs from Johnson & Johnson. Your patients will be connected to the program that aligns with the J&J medicine they’ve been prescribed.
J&J withMe provides your office with educational support to help patients throughout their treatment journey.
Access and Affordability Support
Access and Affordability Support
- Benefits investigation support
- Prior authorization support and status monitoring
- Information on the exceptions and appeals process
- Coding and billing information
- Finding cost support options for eligible patients
Dedicated Support from a Field Reimbursement Manager
Dedicated Support from a Field Reimbursement Manager
- Access, fulfillment, and reimbursement education
- Information on cost support options for eligible patients
- Ability to connect with a specialty pharmacy in case of fulfillment issues
Get Started with J&J withMe
- Visit Portal.JNJwithMe.com to investigate insurance coverage for your patients, enroll your patients in savings, or sign them up for Care Navigator support.
- Visit JNJwithMe.com/hcp/ for access and affordability information for the J&J medicine you prescribed.
- Bookmark these links for quick and easy access!
Questions? Call 833-JNJ-wMe1 (833-565-9631), Monday through Friday, 8:00 AM to 8:00 PM ET.
The patient support and resources provided by J&J withMe are not intended to provide medical advice, replace a treatment plan from the patient’s doctor or nurse, provide case management services, or serve as a reason to prescribe a J&J medicine.
Patients & care partners readiness resources
These tools are designed to help you support your patients through their treatment journey with TECVAYLI® or TALVEY®.
Click the links below to download the TECVAYLI® and TALVEY® readiness resources you may need.
Once the clinical decision has been made to prescribe a Johnson & Johnson medicine:
J&J withMe
J&J withMe
Each patient’s treatment journey is unique. We’re here to help by providing personalized 1-on-1 support for your patients. Your patients will be connected to the program that aligns with the J&J medicine they’ve been prescribed.
Dedicated Care Navigator
Free 1-on-1, personalized support from experienced cancer nurses*
Cost Support
Options regardless of your patients’ insurance type or even if they have no insurance
Resources and Community Connections
Additional resources and connections to support available in their community
Get your patients connected to J&J withMe support by asking them to enroll at: Account.JNJwithMe.com/oncology
OR
Call 833-JNJ-wMe1 (833-565-9631), Monday through Friday, 8:00 AM to 8:00 PM ET.
*Care Navigators do not provide medical advice.
The patient support and resources provided by J&J withMe are not intended to provide medical advice, replace a treatment plan from the patient’s doctor or nurse, provide case management services, or serve as a reason to prescribe a J&J medicine.
Need more?
Visit our Homepage to learn more about the states of readiness to support your operational readiness.
Learn more about the bispecific antibody therapies for RRMM from Johnson & Johnson.
Learn moreHave additional questions about the operational process of treating RRMM with bispecifics?
Learn more